News OpenBind unveils its first AI model for drug discovery A research consortium that aims to make the UK a leader in AI-driven drug discovery, OpenBind, has hit its first major milestone.
News Jury finds Takeda liable for $885m in pay-for-delay lawsuit Takeda is on the hook for $885m damages – which could rise to $2.5bn – in a suit claiming it paid a rival to delay the launch of a generic competitor.
News European study shows inequality in access to new medicines Trade organisation EFPIA says disparities in access to new medicines in Europe may be exacerbated by the US's Most-Favoured Nation (MFN) policy.
News Sanofi says drug for rare disease AATD tops standard care After a phase 2 readout, Sanofi is charting a route to market for AATD therapy efdoralprin alfa, acquired as part of its $2.2bn takeover of Inhibrx.
News SCOTUS won't hear pharma's IRA complaints The US Supreme Court has refused to consider lawsuits from pharma groups challenging Medicare's drug pricing negotiation powers.
News MSD's Sac-TMT delivers in first phase 3 readout MSD's TROP2-targeting antibody-drug conjugate sac-TMT, licensed from China's Kelun, has improved survival in a late-stage endometrial cancer trial.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.